Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 21

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 21
---
 We are entitled to an annual licensing maintenance fee and a 6% royalty on potential future sales.

Full Portfolio Details

We have assembled one of the largest portfolios of biopharmaceutical assets in the industry which provides investors the opportunity to participate in the biotech industry while mitigating the industry’s usual inherent clinical binary risks. Our portfolio consists of assets which currently generate revenue through royalties on commercial products, as well as Captisol sales on commercial products. In addition to these assets, we have a substantial pipeline of development stage assets that currently generate contractual payments through milestone and license fees with future potential for royalties and Captisol material sales for those programs under our Captisol technology.

11

ApprovedPartner NameProgramTherapeutic AreaAcrotech/CASIEvomelaOncologyAlvogen/AdalvoTeriparatideWomen's HealthAlvogen/Hikma/Nanjing King-FriendVoriconazoleInfectious DiseaseAmgen/Beigene/OnoKyprolisOncologyBaxterNexteroneCardiovascularEisaiFycompaCentral Nervous SystemElutiaECM portfolioMedical device/CardiologyExelixis/Daiichi-SankyoMinnebroCardiovascularGileadVekluryInfectious DiseaseIngenusTaxotereOncologyJazzRylazeOncologyMelintaBaxdelaInfectious DiseaseMenariniFrovatriptanCentral Nervous SystemFarevaNoxafil-IVInfectious DiseaseMerckVaxneuvanceInfectious DiseaseMerckCapvaxiveInfectious DiseasePelthosZELSUVMIInfectious DiseaseNovartisMekinistOncologyOutlook TherapeuticsLytenavaOphthalmologyParPosaconazoleInfectious DiseasePfizerDuaveeInflammatory/MetabolicPfizerVfend-IVInfectious DiseaseRecordatiQarzibaOncologySageZulressoCentral Nervous SystemSanofiTzieldMetabolic Sedor/LupinSesquientCentral Nervous SystemSerum Institute of IndiaPneumosilInfectious DiseaseSerum Institute of IndiaMen5Infectious DiseaseTravereFilspariMetabolicVeronaOhtuvayreRespiratory DiseaseXi'an XintongPradefovirInfectious DiseasePhase 3/Pivotal or Regulatory Submission StagePartner NameProgramTherapeutic